Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Savara Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's Biologics License Application (BLA) for MOLBREEVI [4][6]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in Savara between March 7, 2024, and May 23, 2025, to discuss their legal rights [1]. - There is a deadline of November 7, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Savara [4]. - The complaint alleges that Savara and its executives made false statements regarding the MOLBREEVI BLA, which lacked sufficient information for FDA approval [6]. Group 2: Stock Performance Impact - Following the announcement of a refusal to file letter from the FDA regarding the MOLBREEVI BLA, Savara's stock price dropped by $0.90 per share, or 31.69%, closing at $1.94 per share on May 27, 2025 [7]. Group 3: Class Action Participation - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member, with no impact on their ability to share in any recovery [8]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Savara's conduct [9].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake (NASDAQ: MLTX) due to allegations of violations of federal securities laws, particularly concerning misleading statements about its product SLK compared to BIMZELX [4][6]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against MoonLake [4]. - Investors who suffered losses in MoonLake between March 10, 2024, and September 29, 2025, are encouraged to contact the firm to discuss their legal rights [1][9]. - The complaint alleges that MoonLake and its executives made false statements regarding the efficacy and clinical benefits of SLK compared to traditional monoclonal antibodies [6]. Group 2: Stock Performance and Market Reaction - Following the announcement of disappointing results from the Phase 3 VELA program on September 28, 2025, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [7]. - The results indicated that SLK did not demonstrate competitive efficacy relative to BIMZELX, leading to significant investor losses [7]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5]. - The firm has offices in New York, Pennsylvania, California, and Georgia, indicating a broad operational footprint [5].

​Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy Right Now. On October 17, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that the European Medicines Agency adopted a positive opinion for its Libtayo, which treats adults with cutaneous squamous cell carcinoma. Earlier this month, Libtayo was approved by the FDA to treat patients with cutaneous squamous cell carcinoma who are at high risk of recurrence after surgery and radiation. Management exp ...

Lexeo Therapeutics Inc. (NASDAQ:LXEO) is one of the hot stocks to buy with huge upside potential. On October 21, H.C. Wainwright lowered the firm’s price target on Lexeo Therapeutics to $13 from $15 and kept a Buy rating on the shares. The price cut was made as the firm pointed out the share dilution from the most recent equity raise. Earlier on October 17, Leerink analyst Mani Foroohar also lowered the firm’s price target on Lexeo Therapeutics to $18 from $20 with an Outperform rating on the shares. Leer ...

Evaxion (NASDAQ:EVAX) is one of the hot stocks to buy with huge upside potential. On October 20, Lake Street analyst Thomas Flaten raised the firm’s price target on Evaxion Biotech to $11 from $6 and kept a Buy rating on the shares. This sentiment was announced after the company announced two-year Phase 2 data for its personalized cancer vaccine, EVX-01, in advanced melanoma. Lake Street Raises Evaxion (EVAX) PT to $11 Following Positive Two-Year EVX-01 Melanoma Data EVX-01 is a personalized peptide-base ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified Class Period of the upcoming lead plaintiff deadline on December 15, 2025 [1] Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The lawsuit claims that defendants made false or misleading statements regarding the efficacy of their product compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly making materially false and misleading statements regarding its business operations and compliance policies during the Class Period from November 30, 2023, to July 3, 2025 [3][8]. Allegation Details - The lawsuit claims that Jasper lacked necessary controls and procedures to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact the results of ongoing studies and the regulatory and commercial prospects of its products, particularly briquilimab [3]. - The failure to maintain proper controls increased the likelihood of disruptive cost-reduction measures and overstated the company's business and financial prospects [3]. Next Steps - Investors who purchased Jasper shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4][8]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 18, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].

Core Insights - AlphaTON Capital Corp and its subsidiary Cyncado Therapeutics presented new findings at the AACR-NCI-EORTC conference, demonstrating that selective adenosine A2B receptor inhibition has a direct anti-tumor effect in mesothelioma cells, reducing PD-L1 expression and modulating YAP signaling [1][2][3] Clinical Development - The new data supports the efficacy of Cyncado's selective A2B receptor antagonist TT-4, which showed better monotherapy activity than anti-PD-1 and improved tumor control when combined with anti-PD-1, leading to increased immune infiltration [2][3] - TT-4 is advancing towards first-patient dosing expected in Q1 2026, with a focus on translating these findings into clinical applications [4][10] Research Collaboration - The research was conducted in collaboration with the Italian Group for Mesothelioma and other institutions, highlighting the importance of partnerships in advancing cancer therapeutics [1][5] Mechanistic Insights - In human mesothelioma models, hypoxia-linked adenosine signaling was found to increase tumor growth and PD-L1 expression, while selective A2B receptor inhibition effectively reduced cell growth and PD-L1 protein levels [3][4] - In vivo studies demonstrated that TT-4 significantly inhibited tumor growth in immunocompetent models, further enhanced by combination therapy with anti-PD-1 [3][4] Company Overview - AlphaTON Capital is focused on building a strategic reserve of TON tokens and developing the Telegram ecosystem, providing institutional-grade exposure to the TON ecosystem while maintaining transparency as a Nasdaq-listed company [6][7] - Cyncado Therapeutics is developing small molecule adenosine receptor antagonists targeting A2A and A2B receptors to overcome immune suppression in oncology, with TT-4 being the lead program [10]

GRAIL, Inc. (NASDAQ:GRAL) is one of the stocks Jim Cramer put under the spotlight recently. Cramer noted the company’s huge run for the year and stated: “And there’s Grail, a company that has a blood test that can detect cancer, maybe. It’s just got a readout for how the test works, and the results were mixed to positive. Grail immediately took advantage of the huge spike on the news… to do a private placement of $325 million. Now, I’m intrigued by the technology, but the company’s been losing hundreds of ...

Group 1 - The article does not provide any specific content related to a company or industry, as it appears to be a technical issue regarding browser settings and ad-blockers [1]